PFE Pfizer
Beaten-down pharma where cost cuts and oncology restore mid-20s margins, bought well below replacement value.
The story
Pfizer is a mature mega-cap pharma emerging from a post-COVID revenue cliff ($101B to $64B) with GAAP margins temporarily depressed by restructuring and IPR&D write-offs. Its moat rests on a broad commercial infrastructure, Seagen-driven oncology portfolio, and pipeline optionality in obesity and vaccines, but it faces a real 2026-2028 patent cliff on Eliquis and Ibrance. This is a late-life-cycle cash generator being repriced for decline, with credible cost cuts (~$7.7B savings) and new launches as the path back to normalized pharma economics.
Near-term revenue dips ~4% as COVID/Paxlovid tails and Prevnar weakness offset Seagen and new launches, then converge to ~2.2% terminal growth below the risk-free rate as pipeline fills the patent-cliff hole. TTM's 10.8% GAAP margin understates economics; cost realignment and mix recovery support convergence to a sustainable large-cap pharma ~25% operating margin over 7 years. Incremental sales-to-capital of 1.2 reflects R&D-plus-BD reinvestment (not the balance-sheet-bloated 0.42), and a 0.65 beta suits a defensive pharma with negligible failure risk.
Value drivers
| Revenue growth (Y1) | -4.0% |
| Terminal growth | 2.2% |
| Forecast horizon | 8y |
| Target operating margin | 25.0% |
| Years to target margin | 7 |
| Sales-to-capital | 1.20 |
| Beta | 0.65 |
| Failure probability | 3.0% |
| Cost of capital (WACC) | 8.8% |
| Terminal WACC | 9.9% |
Valuation bridge
| PV of explicit FCFF | 60.38B |
| PV of terminal value | 78.13B |
| Equity value | 73.14B |
| ÷ shares → per share | $12.83 |
News
bullish +0.30 · 8 articles
- IP Group PLC (FRA:IOOA) (H1 2026) Earnings Call Highlights: NAV Tops GBP1 Billion as Cash ...
- Sector Update: Healthcare Stocks Higher Late Afternoon
- Can Volume Keep Covering Eli Lilly's Price Cuts?
- What Happens To AbbVie Stock If SKYRIZI Slows Down?
- Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.
- Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears
- Pfizer Raises 2026 Revenue Guidance to $62 Billion. Here’s What’s Behind the Beat
- Is Pfizer's New Business Big Enough To Carry The Old One?
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 61.15B | -4.0% | 12.9% | 7.87B | 0 | 7.87B | 7.23B |
| 2 | 59.24B | -3.1% | 14.9% | 8.82B | 0 | 8.82B | 7.46B |
| 3 | 57.92B | -2.2% | 16.9% | 9.80B | 0 | 9.80B | 7.61B |
| 4 | 57.14B | -1.3% | 18.9% | 10.82B | 0 | 10.82B | 7.73B |
| 5 | 56.88B | -0.5% | 21.0% | 11.92B | 0 | 11.92B | 7.83B |
| 6 | 57.13B | 0.4% | 23.0% | 13.13B | 203.16M | 12.92B | 7.81B |
| 7 | 57.88B | 1.3% | 25.0% | 14.47B | 625.68M | 13.84B | 7.69B |
| 8 | 59.15B | 2.2% | 25.0% | 14.79B | 1.06B | 13.73B | 7.01B |
Key risks
- Eliquis/Ibrance patent expiries 2026-2028 could erode $8-10B+ of high-margin revenue
- Pipeline execution risk after repeated danugipron and obesity setbacks
- IRA drug-price negotiation and China/IRA pricing pressure compressing long-run margins
Catalysts
- Obesity portfolio data readouts (oral danugipron) reframing growth story
- Oncology ramp (Padcev, Elrexfio, Adcetris) plus $7.7B cost-savings program lifting margins toward mid-20s
- Dividend yield near 6.5% and depressed valuation limiting downside as market re-rates normalized earnings